系统性皮质类固醇剂量对喘反应的影响:一项观察性队列研究
Xiao Xu1, Trung N Tran1, Sarowar Golam2
1AstraZeneca, Gaithersburg, MD, USA.
ERJ open research
|January 28, 2025
概括
这项研究将类固醇-SCS使用与喘死亡率联系起来. 较高的类固醇-SCS暴露与喘死亡风险增加相关,表明剂量-反应关系.
科学领域:
- 肺部病理学 肺部病理学
- 药理学 药理学是指药理学的学科.
- 流行病学 流行病学
背景情况:
- 吸入性皮质类固醇 (ICS) 是喘管理的基石.
- 有关ICS使用的潜在长期风险存在担忧,特别是过度使用.
研究的目的:
- 调查吸入性皮质类固醇 (ICS) 的使用和过度使用与喘相关死亡率之间的关联.
- 确定ICS暴露和喘患者的死亡风险之间是否存在剂量反应关系.
主要方法:
- 利用了一个庞大的患者数据库,覆盖了很长一段时间.
- 分析数据以确定ICS使用模式和死亡结果之间的联系.
- 检查的平均每日暴露和累计剂量类别.
主要成果:
- 确定了ICS使用/过度使用和喘死亡率之间的显著关联.
- 证明了积极的剂量反应关系:增加ICS暴露与较高的死亡风险相关.
- 在平均每日暴露和累计剂量指标上,研究结果一致.
结论:
- 吸入性皮质类固醇 (ICS) 的使用,特别是过度使用,与喘死亡率的增加有关.
- 这些发现强调了在喘管理中适当的ICS剂量和监测的重要性.
- 需要进一步的研究来探索这种剂量反应关系的机制和临床影响.
相关概念视频
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
216
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
216
COPD: Management Using Bronchodilators and Corticosteroids
174
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
174
Asthma-II: Pathophysiology and Classification
2.6K
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
2.6K
Antiasthma Drugs: Leukotriene Modifiers
239
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
239
Asthma-IV: Diagnostic and Management
2.5K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.5K
Antiasthma Drugs: β2-Adrenoceptor Agonists
231
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
231


